Michael J. LaBarre serves as the Senior Vice President and Chief Technical Officer at Halozyme Therapeutics Inc., a biopharmaceutical company focused on developing novel oncology therapies. In his role, LaBarre is responsible for overseeing the company's technical operations, including process development, manufacturing, and quality control. His leadership is pivotal in ensuring that Halozyme's innovative treatments are developed and produced to the highest standards, ultimately benefiting patients worldwide. LaBarre's professional journey in the biopharmaceutical industry spans over two decades, during which he has held various leadership positions at renowned companies. Prior to joining Halozyme, he served as the Vice President of Technical Operations at Biogen, where he played a key role in the successful commercialization of multiple sclerosis therapies. LaBarre's expertise in bioprocess development and manufacturing has been instrumental in bringing life-changing treatments to market. His strategic vision and operational excellence have earned him recognition as a thought leader in the industry. Throughout his career, LaBarre has demonstrated a strong commitment to advancing the field of biopharmaceuticals. He has been an active member of several professional organizations, including the International Society for Pharmaceutical Engineering (ISPE), where he has shared his insights on best practices in bioprocessing and manufacturing. At Halozyme, LaBarre continues to drive innovation and operational efficiency, ensuring that the company remains at the forefront of oncology research and development. His contributions have been vital to Halozyme's growth and success, as the company works to improve the lives of patients with cancer.